TL;DR: Beginning in mid-July 2026, the Agency for Healthcare Research and Quality (AHRQ), part of the U.S. Department of Health and Human Services (HHS), began sending grantees near-identical “non-award” letters ending continuation funding for active, multi-year research grants mid-cycle. As of STAT News’ July 22, 2026 reporting, at least 78 grants worth a combined $200 million were affected, with $109.2 million in previously committed but not-yet-disbursed funding withdrawn. Earlier reporting from July 17-19 had put the count lower (dozens of grants, in the tens of millions of dollars), reflecting how quickly the scope was still being confirmed; research administrators should treat the figures below as the most current available rather than final, and should verify against AHRQ/HHS’s own communications for their own institution’s awards.
What happened
Starting around July 17, 2026, researchers holding active AHRQ grants began receiving letters informing them that continuation funding for the next budget period would not be provided. The letters were reported as near-identical in substance across recipients, stating that “AHRQ is adjusting its discretionary health services research award portfolio in order to better prioritize agency resources” toward a stated set of priority areas, reported to include patient safety, antibiotic resistance, artificial intelligence, long COVID, nutrition, and autism research, among others.
Coverage from AcademyHealth and STAT News put the confirmed scope, as of July 22, 2026, at a minimum of 78 grants representing roughly $200 million in total award value, of which $109.2 million in remaining, previously committed funding will not be disbursed. Affected projects were reported to span patient safety, antibiotic stewardship, behavioral health integration, health care cost research, and health services workforce development, core areas of AHRQ’s traditional discretionary research portfolio. Because AHRQ continued issuing letters through the reporting window, research administrators should expect the final count to be confirmed, not assume the July 22 figures are the last word; check current reporting and any direct notice from AHRQ before relying on a specific number for institutional planning.
“Termination” or “non-award”? Why the label matters
A central and consequential dispute in this story is terminology, not just characterization. HHS has stated that the affected grants “were not terminated”, rather, continuation funding for the next budget period simply “was not awarded.” Grant Witness data scientist Scott Delaney was quoted describing this framing as “terminations in different clothes,” arguing the practical effect on researchers and their institutions is identical to a termination regardless of the label applied.
This distinction is not merely semantic for a sponsored programs office. Federal grant regulations under 2 CFR 200 (the Uniform Guidance) draw a meaningful line between terminating an active award before the end of its period of performance, which generally carries specific notice, documentation, and appeal procedures, and simply declining to fund a subsequent, non-competing continuation budget period of a multi-year award, which agencies have historically had broader discretion over. Multi-year federal grants, including most AHRQ research project grants, are typically awarded with an initial, non-competing expectation of continued funding across budget periods contingent on progress and available appropriations; whether ending that expectation mid-project functions, in substance, like a termination, with the same disruption to staff, data collection, human subjects protocols, and subcontracts, is exactly the question grantees and advocacy groups are raising. The label an agency applies can also affect what recourse, if any, a grantee has to challenge the decision, and how the action is recorded in federal grant reporting systems.
The stated rationale: portfolio “prioritization”
The non-award letters reportedly cited a shift in AHRQ’s discretionary health services research portfolio to better align with a stated set of priorities. This kind of top-down portfolio reprioritization, communicated via largely uniform letters rather than individualized programmatic review of each project’s merit or progress, is itself notable for research administrators: it signals that continuation funding decisions were made at a portfolio level rather than case-by-case, which has implications for how principal investigators and their institutions might document and, where applicable, seek clarification on a specific award.
Context matters here too: AHRQ receives approximately $345 million annually in discretionary appropriations from Congress. Reporting from AcademyHealth noted the agency had, at the time of the non-award letters, spent only a small fraction of its fiscal year 2026 appropriation, and was issuing these actions with roughly two months remaining in the fiscal year, timing that has added to grantee and advocacy-group concern about the process and its downstream effects on the health services research field.
What this means for sponsored programs offices
- Institutional exposure isn’t limited to PIs who’ve already been notified. If your institution holds any active AHRQ awards, confirm current funding status directly with program officers rather than assuming a lack of notice means continuation is secure, letters were reported to be still going out through late July 2026.
- Understand the label’s practical consequences before advising a PI. A “non-award” of a continuation budget period may not trigger the same notice, wind-down, or appeal mechanisms that a formal termination under 2 CFR 200 would. Sponsored programs staff should read the specific letter language for each affected award carefully rather than assuming standard termination procedures apply.
- Plan for closeout and effort-reallocation contingencies. Non-competing continuation funding is a routine planning assumption in multi-year award budgeting; a wave of unexpected non-awards is a reminder to build contingency language into institutional risk assessments for federally funded, multi-year health services research portfolios, particularly where a single funder represents concentrated risk.
- Document everything. Given the disputed characterization, institutions with affected awards should preserve the non-award letter, prior award documentation, and any correspondence with AHRQ program staff, useful regardless of whether recourse becomes available later.
Frequently asked questions
How many AHRQ grants have been affected?
As of STAT News’ July 22, 2026 reporting, at least 78 grants had received non-award letters, representing a combined $200 million in award value and $109.2 million in funding that will not be disbursed. Earlier reporting in the days immediately after the letters began (around July 17-19, 2026) cited a smaller, partial count as the story was still developing; the figures here reflect the most complete confirmed tally at publication, not necessarily a final total.
Is this legally a grant termination?
HHS has stated the affected grants were not terminated, only that continuation funding was not awarded for the next budget period. Outside observers, including Grant Witness’s Scott Delaney, have publicly disputed that framing as a distinction without a practical difference. This is an active, contested characterization rather than a settled legal question as of this writing.
What reason did AHRQ give for ending these grants?
The non-award letters reportedly cited a portfolio-wide reprioritization of AHRQ’s discretionary health services research funding toward a stated set of priority areas, including patient safety, antibiotic resistance, artificial intelligence, long COVID, nutrition, and autism research.
Does a “non-award” carry the same appeal rights as a formal termination?
This is one of the substantive open questions the terminology dispute raises. Federal termination actions under 2 CFR 200 generally carry specific notice and dispute procedures; a decision not to fund a non-competing continuation has traditionally been treated with broader agency discretion. Affected institutions should confirm the specific procedural posture of their own award directly with AHRQ and institutional counsel rather than assume either framework applies by default.
Sources
- STAT News, “Federal agency for healthcare quality cancels $109 million in grants,” July 22, 2026
- AcademyHealth, “AHRQ Has Begun Canceling Research Grants. Here’s What We Know,” July 2026
- Becker’s Hospital Review, “AHRQ terminates dozens of patient care research grants: Report”
- Roll Call, “HHS research agency ends funding for dozens of health studies,” July 17, 2026
- Science (AAAS), “Trump administration ends dozens of grants for studying patient care”
This is a developing story. Figures on the number of grants and dollar amounts affected were still being confirmed by journalists and advocacy groups as of late July 2026 and may be revised; check current reporting before relying on a specific figure for institutional decision-making.
